Latest Quarter
2026-04-07
Shanghai Bioheart Biological Technology Co Ltd (2185.HK)
Revenue
$20.9M
Net Income
-$27.2M
Operating Margin
-101.8%
Free Cash Flow
-$167M
Debt / Assets
26.5%
Values are in USD and rounded to the nearest whole number unless noted.
Swipe horizontally to view all columns.
| Income Statement (Quarterly) | 2026-04-07 | 2025-12-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | 20,862,000 | 23,668,425 | 20,862,000 | 10,431,000 |
| Cost of Revenue | 11,167,000 | 25,718,640 | 11,167,000 | 5,583,500 |
| Gross Profit | 9,695,000 | -2,050,214 | 9,695,000 | 4,847,500 |
| Operating Expenses | ||||
| R&D Expenses | 0 | 0 | 0 | 0 |
| SG&A Expenses | 10,837,000 | 7,576,452 | 10,837,000 | 5,418,500 |
| Operating Expenses | 30,927,000 | 47,567,930 | 30,927,000 | 15,463,500 |
| Operating Income | -21,232,000 | -49,618,146 | -21,232,000 | -10,616,000 |
| Interest Expense | 0 | 2,059,064 | 2,728,000 | 0 |
| Income Before Tax | -27,420,000 | -67,438,788 | -27,420,000 | -13,710,000 |
| Income Tax Expense | 686,000 | -26,434,494 | 686,000 | 343,000 |
| Net Income | -27,213,000 | -42,125,274 | -27,213,000 | -13,606,500 |
| Per Share | ||||
| EPS | -0.11 | -0.18 | -0.11 | -0.06 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Statement (Annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | 43,769,109 | 0 | 0 |
| Cost of Revenue | 43,926,916 | 0 | 23,597,232 |
| Gross Profit | -157,806 | 0 | -23,597,232 |
| Operating Expenses | |||
| R&D Expenses | 0 | 0 | 0 |
| SG&A Expenses | 11,527,722 | 19,740,000 | 49,343,685 |
| Operating Expenses | 69,678,723 | 61,040,000 | 163,676,000 |
| Operating Income | -69,836,531 | -61,040,000 | -164,624,000 |
| Interest Expense | 8,515,747 | 0 | 578,000 |
| Income Before Tax | -93,518,334 | -93,324,000 | -188,820,000 |
| Income Tax Expense | -26,855,482 | 0 | 5,541,412 |
| Net Income | -68,239,950 | -87,944,000 | -194,361,412 |
| Per Share | |||
| EPS | -0.28 | -0.36 | -0.80 |
| EPS Diluted | 0.00 | 0.00 | 0.00 |
| Balance Sheet (Quarterly) | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Cash and Cash Equivalents | 92,322,480 | 202,386,000 | 369,438,000 |
| Short Term Investments | 156,307,843 | 0 | 0 |
| Net Receivables | 21,692,276 | 0 | 0 |
| Inventory | 37,254,931 | 27,583,000 | 3,980,000 |
| Total Current Assets | 382,070,388 | 299,027,000 | 408,473,000 |
| Property Plant Equipment | 84,504,137 | 51,578,000 | 30,906,000 |
| Goodwill and Intangibles | 270,775,793 | 282,217,000 | 282,340,000 |
| Total Assets | 832,834,153 | 733,776,000 | 817,899,000 |
| Liabilities | |||
| Account Payables | 2,219,948 | 95,000 | 0 |
| Short Term Debt | 2,246,960 | 1,269,000 | 1,579,000 |
| Total Current Liabilities | 25,041,708 | 19,649,000 | 20,069,000 |
| Long Term Debt | 10,487,484 | 7,014,000 | 183,000 |
| Total Liabilities | 220,473,283 | 53,243,000 | 44,042,000 |
| Shareholders Equity | |||
| Retained Earnings | 0 | -937,280,000 | -849,336,000 |
| Total Shareholders Equity | 435,001,023 | 660,468,000 | 748,412,000 |
| Balance Sheet (Annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Cash and Cash Equivalents | 92,322,480 | 202,386,000 | 369,438,000 |
| Short Term Investments | 156,307,843 | 0 | 0 |
| Net Receivables | 21,692,276 | 0 | 0 |
| Inventory | 37,254,931 | 27,583,000 | 3,980,000 |
| Total Current Assets | 382,070,388 | 299,027,000 | 408,473,000 |
| Property Plant Equipment | 84,504,137 | 51,578,000 | 30,906,000 |
| Goodwill and Intangibles | 270,775,793 | 282,217,000 | 282,340,000 |
| Total Assets | 832,834,153 | 733,776,000 | 817,899,000 |
| Liabilities | |||
| Account Payables | 2,219,948 | 95,000 | 0 |
| Short Term Debt | 2,246,960 | 1,269,000 | 1,579,000 |
| Total Current Liabilities | 25,041,708 | 19,649,000 | 20,069,000 |
| Long Term Debt | 10,487,484 | 7,014,000 | 183,000 |
| Total Liabilities | 220,473,283 | 53,243,000 | 44,042,000 |
| Shareholders Equity | |||
| Retained Earnings | 0 | -937,280,000 | -849,336,000 |
| Total Shareholders Equity | 435,001,023 | 660,468,000 | 748,412,000 |
| Cash Flow Statement (Quarterly) | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Operating Activities | ||
| Net Income | -87,944,000 | -188,820,000 |
| Depreciation & Amortization | 8,174,000 | 21,355,000 |
| Stock Based Compensation | 0 | 47,627,000 |
| Change in Working Capital | -66,565,000 | 45,708,000 |
| Operating Cash Flow | -119,550,000 | -49,028,000 |
| Investing Activities | ||
| Capital Expenditure | -47,140,000 | -17,970,000 |
| Investments | -47,140,000 | -17,715,000 |
| Investing Cash Flow | -46,034,000 | -28,856,000 |
| Financing Activities | ||
| Debt Repayment | -2,120,000 | 0 |
| Common Stock Issued/Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Financing Cash Flow | -2,442,000 | -5,819,000 |
| Summary | ||
| Free Cash Flow | -166,690,000 | -66,998,000 |
| Net Change in Cash | -167,052,000 | -81,880,000 |
| Cash Flow Statement (Annual) | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Operating Activities | ||
| Net Income | -87,944,000 | -188,820,000 |
| Depreciation & Amortization | 8,174,000 | 21,355,000 |
| Stock Based Compensation | 0 | 47,627,000 |
| Change in Working Capital | -66,565,000 | 45,708,000 |
| Operating Cash Flow | -119,550,000 | -49,028,000 |
| Investing Activities | ||
| Capital Expenditure | -47,140,000 | -17,970,000 |
| Investments | -47,140,000 | -17,715,000 |
| Investing Cash Flow | -46,034,000 | -28,856,000 |
| Financing Activities | ||
| Debt Repayment | -2,120,000 | 0 |
| Common Stock Issued/Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Financing Cash Flow | -2,442,000 | -5,819,000 |
| Summary | ||
| Free Cash Flow | -166,690,000 | -66,998,000 |
| Net Change in Cash | -167,052,000 | -81,880,000 |